Characteristics of all patients with second cancers during TKI therapy for CML/MPN
| Patient characteristics (n = 66) . | Median (range) . | No. (%) . |
|---|---|---|
| Age at diagnosis of CML/MPN, y | 57 (29-78) | |
| Age at diagnosis of second cancer, y | 62 (31-85) | |
| WBC count at CML/MPN, × 109/L | 98.9 (12.6-398) | |
| Hemoglobin level at CML/MPN, g/dL | 12.9 (9-18.5) | |
| Platelet count at CML/MPN, × 109/L | 427.5 (97-1440) | |
| Follow-up after CML/MPN, mo | 107 (13-362) | |
| Time from CML/MPN to second cancer, mo* | 68 (4-302) | |
| Time on treatment with TKI until second cancer, mo* | 39 (2-98) | |
| Time on imatinib until second cancer (n = 64), mo* | 39 (0.7-98) | |
| Time on dasatinib until second cancer (n = 8), mo* | 6.5 (0.3-22) | |
| Time on nilotinib until second cancer (n = 4), mo* | 9 (3-14) | |
| Time on bosutinib until second cancer, (n = 2), mo* | 7 (3-20) | |
| Follow-up after diagnosis of second cancer, mo* | 30 (1-121) | |
| History of cancer before TKI therapy | 13 (20) | |
| Duration of CR for previous cancers, mo | 114.5 (9-471) | |
| CML/MPN treatment at time of second cancer* | ||
| Imatinib | 56 (85) | |
| Dasatinib | 6 (9) | |
| Nilotinib | 3 (5) | |
| Bosutinib | 1 (1) |
| Patient characteristics (n = 66) . | Median (range) . | No. (%) . |
|---|---|---|
| Age at diagnosis of CML/MPN, y | 57 (29-78) | |
| Age at diagnosis of second cancer, y | 62 (31-85) | |
| WBC count at CML/MPN, × 109/L | 98.9 (12.6-398) | |
| Hemoglobin level at CML/MPN, g/dL | 12.9 (9-18.5) | |
| Platelet count at CML/MPN, × 109/L | 427.5 (97-1440) | |
| Follow-up after CML/MPN, mo | 107 (13-362) | |
| Time from CML/MPN to second cancer, mo* | 68 (4-302) | |
| Time on treatment with TKI until second cancer, mo* | 39 (2-98) | |
| Time on imatinib until second cancer (n = 64), mo* | 39 (0.7-98) | |
| Time on dasatinib until second cancer (n = 8), mo* | 6.5 (0.3-22) | |
| Time on nilotinib until second cancer (n = 4), mo* | 9 (3-14) | |
| Time on bosutinib until second cancer, (n = 2), mo* | 7 (3-20) | |
| Follow-up after diagnosis of second cancer, mo* | 30 (1-121) | |
| History of cancer before TKI therapy | 13 (20) | |
| Duration of CR for previous cancers, mo | 114.5 (9-471) | |
| CML/MPN treatment at time of second cancer* | ||
| Imatinib | 56 (85) | |
| Dasatinib | 6 (9) | |
| Nilotinib | 3 (5) | |
| Bosutinib | 1 (1) |
WBC indicates white blood cell; and CR, complete remission.
Data reflect time to/from first second cancer identified.